Inex initiates Onco TCS
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Inex begins rolling NDA submission Oct. 1 for its non-Hodgkin's lymphoma agent Onco TCS (liposomal vincristine) with nonclinical safety and pharmacology data. Remaining sections will be submitted before the end of the year. The firm is seeking an indication for relapsed aggressive NHL, but is also studying the agent in first-line NHL, relapsed small cell lung cancer, relapsed Hodgkin's disease, and others...